论文部分内容阅读
原发于肾脏本身和继发于其他疾病的肾损害统称为肾脏疾病,由于对肾脏疾病发病机制的更进一步认识,新药的开发和临床应用近十年取得了长足的进步,对改善肾脏病患者的病情,提高生活质量,延长寿命起到了重要的作用。本文就肾脏疾病的临床用药进展作一综述。1肾素-血管紧张素-醛固酮系统(RAAS)抑制剂(RAASI)近年来几乎所有的实验和临床证实,阻断RAAS能延缓肾脏病的进展,开发阻断RAAS的各种药物不仅为临床治疗提供了崭新的干预手段,也为进一步了解RAAS在各种疾病状态下的作用提供了有利的工具。RAAS包括循环RAAS和局部RAAS,血管紧张素Ⅱ(AⅡ)是RAAS的主要效应物质,根据阻断RAAS的环节不同将RAASI分成:抗血管紧张素原
Kidney itself and secondary to other diseases, kidney damage, collectively referred to as kidney disease, due to the pathogenesis of kidney disease, a better understanding of the development of new drugs and clinical applications made considerable progress in the past decade, to improve kidney disease patients The disease, improve the quality of life, to extend life expectancy has played an important role. This article reviews the clinical progress of renal diseases. 1 Renin-angiotensin-aldosterone system (RAAS) inhibitor (RAASI) Almost all experiments and clinical trials in recent years have demonstrated that blocking RAAS can delay the progression of kidney disease and developing various drugs that block RAAS not only for clinical treatment Provides a new means of intervention, but also to further understand the role of RAAS in a variety of diseases provides an advantageous tool. RAAS includes circulating RAAS and local RAAS, and angiotensin Ⅱ (AⅡ) is the main effector of RAAS. According to the different stages of RAAS, RAASI is divided into: anti-angiotensinogen